Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Publikationer 2006-2010

 

Publikationer från 2010 med länkar till abstrakt i pubmed.

Measurement of vasoactive neuropeptides in biological materials: problems and pitfalls from 30 years of experience and novel future approaches.
Edvinsson L, Ekman R, Goadsby PJ. Cephalalgia. 2010 Jun;30(6):761-6. Review. No abstract available.

 Aβ40 oligomers identified as a potential biomarker for the diagnosis of Alzheimer's disease.
Gao CM, Yam AY, Wang X, Magdangal E, Salisbury C, Peretz D, Zuckermann RN, Connolly MD, Hansson O, Minthon L, Zetterberg H, Blennow K, Fedynyshyn JP, Allauzen S. PLoS One. 2010 Dec 302.

{gamma}-Secretase-dependent amyloid-{beta} is increased in Niemann-Pick type C: A cross-sectional study.
Mattsson N, Zetterberg H, Bianconi S, Yanjanin NM, Fu R, Månsson JE, Porter FD, Blennow K. Neurology. 2010 Dec 29. [Epub ahead of print]

Neuroinflammation Screening in Immunotherapy Trials against Alzheimer's Disease.
Andreasen N, Blennow K, Zetterberg H. Int J Alzheimers Dis. 2010 Dec 19;2010:638379.PMID: 21197432 [PubMed - in process]Free PMC ArticleFree text


The cognitive profile and CSF biomarkers in dementia with Lewy bodies and Parkinson's disease dementia.
Andersson M, Zetterberg H, Minthon L, Blennow K, Londos E. Int J Geriatr Psychiatry. 2011 Jan

Impaired Lipoprotein Receptor-Mediated Peripheral Binding of Plasma Amyloid-β is an Early Biomarker for Mild Cognitive Impairment Preceding Alzheimer's Disease.
Sagare AP, Deane R, Zetterberg H, Wallin A, Blennow K, Zlokovic BV.
J Alzheimers Dis. 2010 Dec 14. [Epub ahead of print]

Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease.
Zetterberg H, Mattsson N, Blennow K, Olsson B. Alzheimers Res Ther. 2010 Nov 30;2(6):32. [Epub ahead of print]

S-100B is superior to NSE, BDNF and GFAP in predicting outcome of resuscitation from cardiac arrest with hypothermia treatment.
Mörtberg E, Zetterberg H, Nordmark J, Blennow K, Rosengren L, Rubertsson S.Resuscitation. 2010 Nov 9. [Epub ahead of print]

CSF amyloid {beta}38 as a novel diagnostic marker for dementia with Lewy bodies.
Mulugeta E, Londos E, Ballard C, Alves G, Zetterberg H, Blennow K, Skogseth R, Minthon L, Aarsland D. J Neurol Neurosurg Psychiatry. 2010 Nov 3. [Epub ahead of print]

CSF Levels of Heart Fatty Acid Binding Protein are Altered During Early Phases of Alzheimer's Disease.
Chiasserini D, Parnetti L, Andreasson U, Zetterberg H, Giannandrea D, Calabresi P, Blennow K. Int J Alzheimers Dis. 2010 Oct 7. [Epub ahead of print]

cNEUPRO: Novel Biomarkers for Neurodegenerative Diseases.
Spitzer P, Klafki HW, Blennow K, Buée L, Esselmann H, Herruka SK, Jimenez C, Klivenyi P, Lewczuk P, Maler JM, Markus K, Meyer HE, Morris C, Müller T, Otto M, Parnetti L, Soininen H, Schraen S, Teunissen C, Vecsei L, Zetterberg H, Wiltfang J. Int J Alzheimers Dis. 2010 Sep 19

Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer's disease.
Parnetti L, Chiasserini D, Andreasson U, Ohlson M, Hüls C, Zetterberg H, Minthon L, Wallin AK, Andreasen N, Talesa VN, Blennow K. Acta Neurol Scand. 2010 Sep 29. doi: 10.1111/j.1600-0404.2010.01435.x. [Epub ahead of print]

Plasma ANP and BNP during exercise in patients with major depressive disorder and in healthy controls.
Wisén AG, Ekberg K, Wohlfart B, Ekman R, Westrin A.J Affect Disord. 2010 Sep 27. [Epub ahead of print]

Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease.
Thorsell A, Bjerke M, Gobom J, Brunhage E, Vanmechelen E, Andreasen N, Hansson O, Minthon L, Zetterberg H, Blennow K. Brain Res. 2010 Sep 25. [Epub ahead of print]

BACE1 gene variants do not influence BACE1 activity, levels of APP or Aβ isoforms in CSF in Alzheimer's disease.
Sjölander A, Zetterberg H, Andreasson U, Minthon L, Blennow K. Mol Neurodegener. 2010 Sep 17;5:37.

Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid.
Bjerke M, Portelius E, Minthon L, Wallin A, Anckarsäter H, Anckarsäter R, Andreasen N, Zetterberg H, Andreasson U, Blennow K. Int J Alzheimers Dis. 2010 Jul 15

Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease.
Mattsson N, Zetterberg H, Blennow K. Int J Alzheimer Dis. 2010 Jul 8 

Cerebrospinal fluid insulin during non-neurological surgery.
Bromander S, Anckarsäter R, Ahrén B, Kristiansson M, Blennow K, Holmäng A, Zetterberg H, Anckarsäter H, Wass CE. J Neural Transm. 2010 Aug 10. [Epub ahead of print]. 

Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people.
De Meyer G, Shapiro F, Vanderstichele H, Vanmechelen E, Engelborghs S, De Deyn PP, Coart E, Hansson O, Minthon L, Zetterberg H, Blennow K, Shaw L, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative.Arch Neurol. 2010 Aug;67(8) 

Evaluation of CSF Biomarkers as Predictors of Alzheimer's Disease: A Clinical Follow-Up Study of 4.7 Years.
Hertze J, Minthon L, Zetterberg H, Vanmechelen E, Blennow K, Hansson O. J Alzheimers Dis. 2010 Aug 6. [Epub ahead of print] 

Effects of cerebrovascular disease on amyloid precursor protein metabolites in cerebrospinal fluid.
Selnes P, Blennow K, Zetterberg H, Grambaite R, Rosengren L, Johnsen L, Stenset V, Fladby T. Cerebrospinal Fluid Res. 2010 Jul 30;7:10. 

No neurochemical evidence of brain injury after blast overpressure by repeated explosions or firing heavy weapons.
Blennow K, Jonsson M, Andreasen N, Rosengren L, Wallin A, Hellström PA, Zetterberg H. Acta Neurol Scand. 2010 Jul 18. [Epub ahead of print] 

Acute Effect on the Abeta Isoform Pattern in CSF in Response to gamma-Secretase Modulator and Inhibitor Treatment in Dogs.
Portelius E, Van Broeck B, Andreasson U, Gustavsson MK, Mercken M, Zetterberg H, Borghys H, Blennow K. J Alzheimers Dis. 2010 Jul 15. [Epub ahead of print]

Proteomic profiling of cerebrospinal fluid in parkinsonian disorders.
Constantinescu R, Andreasson U, Li S, Podust VN, Mattsson N, Anckarsäter R, Anckarsäter H, Rosengren L, Holmberg B, Blennow K, Wikkelsö C, Rüetschi U, Zetterberg H. Parkinsonism Relat Disord. 2010 Jul 8. [Epub ahead of print]

Neurochemical measures co-vary with personality traits: Forensic psychiatric findings replicated in a general population sample.
Nilsson T, Bromander S, Anckarsäter R, Kristiansson M, Forsman A, Blennow K, Zetterberg H, Anckarsäter H, Wass C. Psychiatry Res. 2010 Aug 15;178(3):525-530. Epub 2010 Jul

Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives.
Hampel H, Frank R, Broich K, Teipel SJ, Katz RG, Hardy J, Herholz K, Bokde AL, Jessen F, Hoessler YC, Sanhai WR, Zetterberg H, Woodcock J, Blennow K. Nat Rev Drug Discov. 2010 Jul;9(7):560-74.

Non-suicidal self-injurious behavior, endogenous opioids and monoamine neurotransmitters.
Stanley B, Sher L, Wilson S, Ekman R, Huang YY, Mann JJ.J Affect Disord. 2010 Jul;124(1-2):134-40. Epub 2009 Nov 25.

Covariation of plasma ghrelin and motilin in irritable bowel syndrome.
Sjölund K, Ekman R, Wierup N.eptides. 2010 Jun;31(6):1109-12. Epub 2010 Mar 23.

Review.Measurement of vasoactive neuropeptides in biological materials: problems and pitfalls from 30 years of experience and novel future approaches.
Edvinsson L, Ekman R, Goadsby PJ.Cephalalgia. 2010 Jun;30(6):761-6.

Genetic Variation of the Ghrelin Signaling System in Females With Severe Alcohol Dependence. 
Landgren S, Jerlhag E, Hallman J, Oreland L, Lissner L, Strandhagen E, Thelle DS, Zetterberg H, Blennow K, Engel JA. Alcohol Clin Exp Res. 2010 Jun 25. [Epub ahead of print]

Neuroinflammation in Lyme neuroborreliosis affects amyloid metabolism.
Mattsson N, Bremell D, Anckarsäter R, Blennow K, Anckarsäter H, Zetterberg H, Hagberg L. BMC Neurol. 2010 Jun 22;10:51

Association of the RAGE G82S polymorphism with Alzheimer's disease.
Daborg J, von Otter M, Sjölander A, Nilsson S, Minthon L, Gustafson DR, Skoog I, Blennow K, Zetterberg H.J Neural Transm. 2010 Jul;117(7):861-7. Epub 2010 Jun 22.

CSF amyloid-{beta} and tau proteins, and cognitive performance, in early and untreated Parkinson's Disease: the Norwegian ParkWest study.
Alves G, Brønnick K, Aarsland D, Blennow K, Zetterberg H, Ballard C, Kurz MW, Andreasson U, Tysnes OB, Larsen JP, Mulugeta E. J Neurol Neurosurg Psychiatry. 2010 Jun 14. [Epub ahead of print]

Low incidence of post-lumbar puncture headache in 1,089 consecutive memory clinic patients.
Zetterberg H, Tullhög K, Hansson O, Minthon L, Londos E, Blennow K.Eur Neurol. 2010;63(6):326-30. Epub 2010 Jun 3. 

Cerebrospinal Fluid Secretory Ca(2 )-Dependent Phospholipase A2 Activity: A Biomarker of Blood-Cerebrospinal Fluid Barrier Permeability.
Chalbot S, Zetterberg H, Blennow K, Fladby T, Grundke-Iqbal I, Iqbal K.Neurosci Lett. 2010 May 11. [Epub ahead of print]

CSF biomarkers predict a more malignant outcome in Alzheimer disease. 
Wallin AK, Blennow K, Zetterberg H, Londos E, Minthon L, Hansson O.Neurology. 2010 May 11;74(19):1531-7

Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects.
Trojanowski JQ, Vandeerstichele H, Korecka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter WZ, Weiner MW, Jack CR Jr, Jagust W, Toga AW, Lee VM, Shaw LM; Alzheimer's Disease Neuroimaging Initiative.Alzheimers Dement. 2010 May;6(3):230-8.

Is it time for biomarker-based diagnostic criteria for prodromal Alzheimer's disease?
Blennow K, Zetterberg H. Alzheimers Res Ther. 2010 Apr 30;2(2):8. [Epub ahead of print]

Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease.
Portelius E, Bogdanovic N, Gustavsson MK, Volkmann I, Brinkmalm G, Zetterberg H, Winblad B, Blennow K.Acta Neuropathol. 2010 Apr 24. [Epub ahead of print]

High Education May Offer Protection Against Tauopathy in Patients with Mild Cognitive Impairment.
Rolstad S, Nordlund A, Eckerström C, Gustavsson MH, Blennow K, Olesen PJ, Zetterberg H, Wallin A.J Alzheimers Dis. 2010 Apr 22. [Epub ahead of print]

Gamma-glutamyltransferase in alcohol use disorders: Modification of decision limits in relation to treatment goals?
Balldin J, Berggren U, Berglund K, Blennow K, Fahlke C, Zetterberg H.Scand J Clin Lab Invest. 2010 Apr;70(2):71-4.Balldin J, Berggren U, Berglund K, Blennow K, Fahlke C, Zetterberg H.Scand J Clin Lab Invest. 2010 Apr;70(2):71-4.

Converging Pathways of Chromogranin and Amyloid Metabolism in the Brain.
Mattsson N, Johansson P, Hansson O, Wallin A, Johansson JO, Andreasson U, Andersen O, Haghighi S, Olsson M, Stridsberg M, Svensson J, Blennow K, Zetterberg H. J Alzheimers Dis. 2010 Apr 22. [Epub ahead of print]

Proteomics Profiling of Single Organs from Individual Adult Zebrafish.  Supplementary data 1 (1394 proteins).xls Supplementary data 2 (644 proteins).xls
Abramsson A, Westman-Brinkmalm A, Pannee J, Gustavsson M, von Otter M, Blennow K, Brinkmalm G, Kettunen P, Zetterberg H.
Zebrafish. 2010 Apr 14. [Epub ahead of print]

Combination of Hippocampal Volume and Cerebrospinal Fluid Biomarkers Improves Predictive Value in Mild Cognitive Impairment.
Eckerström C, Andreasson U, Olsson E, Rolstad S, Blennow K, Zetterberg H, Malmgren H, Edman A, Wallin A.Dement Geriatr Cogn Disord. 2010 Apr 9;29(4):294-300. [Epub ahead of print]

Biochemical markers in Alzheimer's disease clinical trials.
Zetterberg H, Mattson N, Shaw LM, Blennow K. Biomark Med. 2010 Feb;4(1):91-8.

A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer's disease.
Portelius E, Dean RA, Gustavsson MK, Andreasson U, Zetterberg H, Siemers E, Blennow K. Alzheimers Res Ther. 2010 Mar 29;2(2):7. [Epub ahead of print]

Memory in individuals with mild cognitive impairment in relation to APOE and CSF Abeta42. 
Thorvaldsson V, Nordlund A, Reinvang I, Blennow K, Zetterberg H, Wallin A, Johansson B. Int Psychogeriatr. 2010 Mar 26:1-9. [Epub ahead of print]

Pittsburgh compound-B and Alzheimer's disease biomarkers in CSF, plasma and urine: An exploratory study.
Degerman Gunnarsson M, Lindau M, Wall A, Blennow K, Darreh-Shori T, Basu S, Nordberg A, Larsson A, Lannfelt L, Basun H, Kilander L.Dement Geriatr Cogn Disord. 2010;29(3):204-12. Epub 2010 Mar 20.

Ubiquitin carboxy-terminal hydrolase L1 (UCHL1) S18Y polymorphism in Alzheimer's disease. Zetterberg M, Sjölander A, von Otter M, Palmér MS, Landgren S, Minthon L, Wallin A, Andreasen N, Blennow K, Zetterberg H. Mol Neurodegener. 2010 Mar 19;5:11.

Cerebrospinal fluid biomarker results in relation to neuropathological dementia diagnoses.
Brunnström H, Rawshani N, Zetterberg H, Blennow K, Minthon L, Passant U, Englund E. Alzheimers Dement. 2010 Mar;6(2):104-9.

Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall.
Mattsson N, Blennow K, Zetterberg H. Clin Chem Lab Med. 2010 Mar 5. [Epub ahead of print]

Association of Nrf2-encoding NFE2L2 haplotypes with Parkinson's disease.
von Otter M, Landgren S, Nilsson S, Celojevic D, Bergström P, Håkansson A, Nissbrandt H, Drozdzik M, Bialecka M, Kurzawski M, Blennow K, Nilsson M, Hammarsten O, Zetterberg H. BMC Med Genet. 2010 Mar 2;11:36.

Converging molecular pathways in human neural development and degeneration.
Mattsson N, Sävman K, Osterlundh G, Blennow K, Zetterberg H. Neurosci Res. 2010 Mar;66(3):330-2. Epub 2009 Dec 2. 

11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.
Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA, Rodriguez Martinez de Liano S, Liu E, Koller M, Gregg KM, Schenk D, Black R, Grundman M. Lancet Neurol. 2010 Apr;9(4):363-72. Epub 2010 Feb 26.

Analysis of lipid pathway genes indicates association of sequence variation near SREBF1/TOM1L2/ATPAF2 with dementia risk.
Reynolds CA, Hong MG, Eriksson UK, Blennow K, Wiklund F, Johansson B, Malmberg B, Berg S, Alexeyenko A, Grönberg H, Gatz M, Pedersen NL, Prince JA. Hum Mol Genet. 2010 Mar 2. [Epub ahead of print]

The stability of AQT processing speed, ADAS-Cog and MMSE during acetylcholinesterase inhibitor treatment in Alzheimer's disease.
Wiig EH, Annas P, Basun H, Andreasen N, Lannfelt L, Zetterberg H, Blennow K, Minthon L. Acta Neurol Scand. 2010 Mar;121(3):186-93. Epub 2009 Sep 24.

PBT2 Rapidly Improves Cognition in Alzheimer's Disease: Additional Phase II Analyses.
Faux NG, Ritchie CW, Gunn A, Rembach A, Tsatsanis A, Bedo J, Harrison J, Lannfelt L, Blennow K, Zetterberg H, Ingelsson M, Masters CL, Tanzi RE, Cummings JL, Herd CM, Bush AI. J Alzheimers Dis. 2010 Feb 17. [Epub ahead of print]

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Blennow K, Hampel H, Weiner M, Zetterberg H. Nat Rev Neurol. 2010 Mar;6(3):131-44. Epub 2010 Feb 16.

Distinct cerebrospinal fluid amyloid beta peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer's disease. Portelius E, Andreasson U, Ringman JM, Buerger K, Daborg J, Buchhave P, Hansson O, Harmsen A, Gustavsson MK, Hanse E, Galasko D, Hampel H, Blennow K, Zetterberg H.Mol Neurodegener. 2010 Jan 14;5:2.

Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults.
Stomrud E, Hansson O, Zetterberg H, Blennow K, Minthon L, Londos E.Arch Neurol. 2010 Feb;67(2):217-23.

Phosphorylated tau 231, memory decline and medial temporal atrophy in normal elders.
Glodzik L, de Santi S, Tsui WH, Mosconi L, Zinkowski R, Pirraglia E, Wang HY, Li Y, Rich KE, Zetterberg H, Blennow K, Mehta P, de Leon MJ.Neurobiol Aging. 2010 Feb 2. [Epub ahead of print]

Is there a CSF biomarker profile related to depression in elderly women? 
Gudmundsson P, Skoog I, Waern M, Blennow K, Zetterberg H, Rosengren L, Gustafson D.Psychiatry Res. 2010 Apr 30;176(2-3):174-8. Epub 2010 Feb 4.

Platelet monoamine oxidase B activity did not predict destructive personality traits or violent recidivism: a prospective study in male forensic psychiatric examinees.
Gustavson C, Wass C, Mansson JE, Blennow K, Forsman A, Anckarsater H, Nilsson T. Neuropsychobiology. 2010;61(2):87-96. Epub 2010 Jan 16.

Nrf2-encoding NFE2L2 haplotypes influence disease progression but not risk in Alzheimer's disease and age-related cataract.
von Otter M, Landgren S, Nilsson S, Zetterberg M, Celojevic D, Bergström P, Minthon L, Bogdanovic N, Andreasen N, Gustafson DR, Skoog I, Wallin A, Tasa G, Blennow K, Nilsson M, Hammarsten O, Zetterberg H. Mech Ageing Dev. 2010 Feb;131(2):105-10. Epub 2010 Jan 12.

Brain Atrophy in Healthy Aging Is Related to CSF Levels of A{beta}1-42. 
Fjell AM, Walhovd KB, Fennema-Notestine C, McEvoy LK, Hagler DJ, Holland D, Blennow K, Brewer JB, Dale AM; the Alzheimer’s Disease Neuroimaging Initiative. Cereb Cortex. 2010 Jan 4. [Epub ahead of print]

Comparison between choir singing and group discussion in irritable bowel syndrome patients over one year: saliva testosterone increases in new choir singers.
Grape C, Wikström BM, Ekman R, Hasson D, Theorell T.Psychother Psychosom. 2010;79(3):196-8. Epub 2009 Oct 15.

 

 

Publikationer från 2009 med länkar till abstrakt i pubmed.

 

Computerized cognition assessment during acetylcholinesterase inhibitor treatment in Alzheimer's disease.
Wesnes K, Edgar C, Andreasen N, Annas P, Basun H, Lannfelt L, Zetterberg H, Blennow K, Minthon L. Acta Neurol Scand. 2009 Dec 28. [Epub ahead of print]

Amyloid and tau cerebrospinal fluid biomarkers in HIV infection.
Gisslén M, Krut J, Andreasson U, Blennow K, Cinque P, Brew BJ, Spudich S, Hagberg L, Rosengren L, Price RW, Zetterberg H.BMC Neurol. 2009 Dec 22;9:63.

Effects of gamma-secretase inhibition on the amyloid beta isoform pattern in a mouse model of Alzheimer's disease.
Portelius E, Zhang B, Gustavsson MK, Brinkmalm G, Westman-Brinkmalm A, Zetterberg H, Lee VM, Trojanowski JQ, Blennow K. Neurodegener Dis. 2009;6(5-6):258-62. Epub 2009 Dec 3.

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.
Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, Honig LS, Doody R, van Dyck CH, Mulnard R, Barakos J, Gregg KM, Liu E, Lieberburg I, Schenk D, Black R, Grundman M; Bapineuzumab 201 Clinical Trial Investigators. Neurology. 2009 Dec 15;73(24):2061-70. Epub 2009 Nov 18.

Kinesin Light Chain 1 Gene Haplotypes in Three Conformational Diseases.
von Otter M, Landgren S, Nilsson S, Lundvall C, Minthon L, Bogdanovic N, Andreasen N, Gustafson DR, Skoog I, Wallin A, Håkansson A, Nissbrandt H, Zetterberg M, Tasa G, Blennow K, Zetterberg H. Neuromolecular Med. 2009 Nov 13. [Epub ahead of print]

Monocyte chemotactic protein-1 (MCP-1) and growth factors called into question as markers of prolonged psychosocial stress.
Jonsdottir IH, Hägg DA, Glise K, Ekman R.PLoS One. 2009 Nov 3;4(11):e7659.

Subcortical vascular dementia biomarker pattern in mild cognitive impairment.
Bjerke M, Andreasson U, Rolstad S, Nordlund A, Lind K, Zetterberg H, Edman A, Blennow K, Wallin A. Dement Geriatr Cogn Disord. 2009;28(4):348-56. Epub 2009 Oct 27.

Cerebrospinal fluid secretory Ca2 -dependent phospholipase A2 activity is increased in Alzheimer disease.
Chalbot S, Zetterberg H, Blennow K, Fladby T, Grundke-Iqbal I, Iqbal K.Clin Chem. 2009 Dec;55(12):2171-9. Epub 2009 Oct 22.

Cerebrospinal fluid biomarkers of white matter lesions - cross-sectional results from the LADIS study.
Jonsson M, Zetterberg H, van Straaten E, Lind K, Syversen , Edman A, Blennow K, Rosengren L, Pantoni L, Inzitari D, Wallin A. Eur J Neurol. 2009 Oct 21. [Epub ahead of print]

Cerebrospinal fluid total tau is associated with shorter survival in dementia with Lewy bodies.
Boström F, Hansson O, Blennow K, Gerhardsson L, Lundh T,Minthon L, Zetterberg H, Londos E. Dement Geriatr Cogn Disord. 2009;28(4):314-9. Epub 2009 Oct 21

No Association of VEGF Polymorphims with Alzheimer's Disease.
Landgren S, Palmér MS, Skoog I, Minthon L, Wallin A, Andreasen N, Zetterberg M, Blennow K, Zetterberg H. Neuromolecular Med. 2009 Oct 20. [Epub ahead of print]

Biological markers of amyloid beta-related mechanisms in Alzheimer's disease.
Hampel H, Shen Y, Walsh DM, Aisen P, Shaw LM, Zetterberg H, Trojanowski JQ, Blennow K. Exp Neurol. 2009 Oct 6. [Epub ahead of print]

Lower CSF HVA and 5-HIAA in bipolar disorder type 1 with a history of childhood ADHD.
Rydén E, Johansson C, Blennow K, Landén M. J Neural Transm. 2009 Dec;116(12):1667-74. Epub 2009 Sep 12.

The acute response of plasma brain-derived neurotrophic factor as a result of exercise in major depressive disorder.
Gustafsson G, Lira CM, Johansson J, Wisén A, Wohlfart B, Ekman R, Westrin A.Psychiatry Res. 2009 Oct 30;169(3):244-8. Epub 2009 Sep 3.

The apolipoprotein E varepsilon4 allele plays pathological roles in AD through high protein expression and interaction with butyrylcholinesterase.
Darreh-Shori T, Modiri N, Blennow K, Baza S, Kamil C, Ahmed H, Andreasen N, Nordberg A. Neurobiol Aging. 2009 Aug 25. [Epub ahead of print]

Association of nAChR gene haplotypes with heavy alcohol use and body mass.
Landgren S, Engel JA, Andersson ME, Gonzalez-Quintela A, Campos J, Nilsson S, Zetterberg H, Blennow K, Jerlhag E. Brain Res. 2009 Dec 11;1305 Suppl:S72-9. Epub 2009 Aug 19.

Biomarkers in the cerebrospinal fluid and neurodegeneration in Langerhans cell histiocytosis.
Gavhed D, Akefeldt SO, Osterlundh G, Laurencikas E, Hjorth L, Blennow K, Rosengren L, Henter JI. Pediatr Blood Cancer. 2009 Dec 15;53(7):1264-70.

Cognitive reserve in relation to abeta42 in patients converting from MCI to dementia - a follow-up report.
Rolstad S, Nordlund A, Eckerström C, Gustavsson MH, Zetterberg H, Wallin A. Dement Geriatr Cogn Disord. 2009;28(2):110-5. Epub 2009 Aug 13.

Concentrations of metals, beta-amyloid and tau-markers in cerebrospinal fluid in patients with Alzheimer's disease.
Gerhardsson L, Blennow K, Lundh T, Londos E, Minthon L. Dement Geriatr Cogn Disord. 2009;28(1):88-94. Epub 2009 Aug 12.

Effects of memantine on cerebrospinal fluid biomarkers of neurofibrillary pathology.
Glodzik L, De Santi S, Rich KE, Brys M, Pirraglia E, Mistur R, Switalski R, Mosconi L, Sadowski M, Zetterberg H, Blennow K, de Leon MJ. J Alzheimers Dis. 2009 Nov;18(3):509-13.

Dopamine D2 receptor genotype is associated with increased mortality at a 10-year follow-up of alcohol-dependent individuals.
Berggren U, Fahlke C, Berglund KJ, Wadell K, Zetterberg H, Blennow K, Thelle D, Balldin J. Alcohol Alcohol. 2010 Jan-Feb;45(1):1-5. Epub 2009 Aug 4.

Sequence variation in SORL1 and dementia risk in Swedes.
Reynolds CA, Hong MG, Eriksson UK, Blennow K, Johansson B, Malmberg B, Berg S, Gatz M, Pedersen NL, Bennet AM, Prince JA. Neurogenetics. 2010 Feb;11(1):139-42. Epub 2009 Aug 4.

Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity.
Sämgård K, Zetterberg H, Blennow K, Hansson O, Minthon L, Londos E. Int J Geriatr Psychiatry. 2010 Apr;25(4):403-10.

Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinson's disease and atypical Parkinsonian disorders.
Constantinescu R, Rosengren L, Johnels B, Zetterberg H, Holmberg B. Parkinsonism Relat Disord. 2010 Feb;16(2):142-5. Epub 2009 Jul 31.

Sustained release of neuron-specific enolase to serum in amateur boxers.
Zetterberg H, Tanriverdi F, Unluhizarci K, Selcuklu A, Kelestimur F, Blennow K. Brain Inj. 2009 Aug;23(9):723-6.

CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosén E, Aarsland D, Visser PJ, Schröder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttilä T, Wallin A, Jönhagen ME, Minthon L, Winblad B, Blennow K. JAMA. 2009 Jul 22;302(4):385-93.

Longitudinal study of CSF biomarkers in patients with Alzheimer's disease.
Buchhave P, Blennow K, Zetterberg H, Stomrud E, Londos E, Andreasen N, Minthon L, Hansson O. PLoS One. 2009 Jul 17;4(7):e6294.

A survey of ABCA1 sequence variation confirms association with dementia.
Reynolds CA, Hong MG, Eriksson UK, Blennow K, Bennet AM, Johansson B, Malmberg B, Berg S, Wiklund F, Gatz M, Pedersen NL, Prince JA. Hum Mutat. 2009 Sep;30(9):1348-54.

A novel pathway for amyloid precursor protein processing.
Portelius E, Price E, Brinkmalm G, Stiteler M, Olsson M, Persson R, Westman-Brinkmalm A, Zetterberg H, Simon AJ, Blennow K. Neurobiol Aging. 2009 Jul 13. [Epub ahead of print]

Motilin concentrations in relation to gastro intestinal dysmotility in diabetes mellitus.
Pendleton H, Ekman R, Olsson R, Ekberg O, Ohlsson B. Eur J Intern Med. 2009 Oct;20(6):654-9. Epub 2009 Jul 12

Relationship between elevated cerebrospinal fluid levels of plasminogen activator inhibitor 1 and neuronal destruction in patients with neuropsychiatric systemic lupus erythematosus.
Kwieciński J, Kłak M, Trysberg E, Blennow K, Tarkowski A, Jin T. Arthritis Rheum. 2009 Jul;60(7):2094-101.

Identification of novel N-terminal fragments of amyloid precursor protein in cerebrospinal fluid.
Portelius E, Brinkmalm G, Tran A, Andreasson U, Zetterberg H, Westman-Brinkmalm A, Blennow K, Ohrfelt A. Exp Neurol. 2009 Jun 25. [Epub ahead of print]

Validation of Alzheimer's disease CSF and plasma biological markers: the multicentre reliability study of the pilot European Alzheimer's Disease Neuroimaging Initiative (E-ADNI).
Buerger K, Frisoni G, Uspenskaya O, Ewers M, Zetterberg H, Geroldi C, Binetti G, Johannsen P, Rossini PM, Wahlund LO, Vellas B, Blennow K, Hampel H. Exp Gerontol. 2009 Sep;44(9):579-85. Epub 2009 Jun 16.

Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study.
Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund LO, Freund-Levi Y, Tsolaki M, Minthon L, Wallin AK, Hampel H, Bürger K, Pirttila T, Soininen H, Rikkert MO, Verbeek MM, Spiru L, Blennow K. Lancet Neurol. 2009 Jul;8(7):619-27. Epub 2009 Jun 10.

Medial temporal lobe atrophy increases the specificity of cerebrospinal fluid biomarkers in Alzheimer disease with minor cerebrovascular changes.
Zhang Y, Londos E, Minthon L, Wattmo C, Blennow K, Liu HJ, Bronge L, Aspelin P, Wahlund LO. Acta Radiol. 2009 Jul;50(6):674-81.

B-type natriuretic peptide plasma levels are elevated in subcortical vascular dementia.
Kondziella D, Göthlin M, Fu M, Zetterberg H, Wallin A. Neuroreport. 2009 Jun 17;20(9):825-7.

Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype.
Blom ES, Giedraitis V, Zetterberg H, Fukumoto H, Blennow K, Hyman BT, Irizarry MC, Wahlund LO, Lannfelt L, Ingelsson M. Dement Geriatr Cogn Disord. 2009;27(5):458-64. Epub 2009 May 7.

The szilard hypothesis on the nature of aging revisited.
Zetterberg H, Båth M, Zetterberg M, Bernhardt P, Hammarsten O. Genetics. 2009 May;182(1):3-9.

A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease.
Verwey NA, van der Flier WM, Blennow K, Clark C, Sokolow S, De Deyn PP, Galasko D, Hampel H, Hartmann T, Kapaki E, Lannfelt L, Mehta PD, Parnetti L, Petzold A, Pirttila T, Saleh L, Skinningsrud A, Swieten JC, Verbeek MM, Wiltfang J, Younkin S, Scheltens P, Blankenstein MA. Ann Clin Biochem. 2009 May;46(Pt 3):235-40. Epub 2009 Apr 2.

CSF antithrombin III and disruption of the blood-brain barrier.
Zetterberg H, Andreasson U, Blennow K. J Clin Oncol. 2009 May 1;27(13):2302-3; author reply 2303-4. Epub 2009 Mar 30. No abstract available.

Use of CSF biomarkers in Alzheimer's disease clinical trials.
Blennow K, Zetterberg H. J Nutr Health Aging. 2009 Apr;13(4):358-61. No abstract available.

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.
Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative. Ann Neurol. 2009 Apr;65(4):403-13.

Thrombocytopenia in early alcohol withdrawal is associated with development of delirium tremens or seizures.
Berggren U, Fahlke C, Berglund KJ, Blennow K, Zetterberg H, Balldin J. Alcohol Alcohol. 2009 Jul-Aug;44(4):382-6. Epub 2009 Mar 16.

Evolution of Abeta42 and Abeta40 levels and Abeta42/Abeta40 ratio in plasma during progression of Alzheimer's disease: a multicenter assessment.
Blennow K, De Meyer G, Hansson O, Minthon L, Wallin A, Zetterberg H, Lewczuk P, Vanderstichele H, Vanmechelen E, Kornhuber J, Wiltfang J; KND-Study Group, Heuser I, Maier W, Luckhaus C, Rüther E, Hüll M, Jahn H, Gertz HJ, Frölich L, Hampel H, Pernetzki R. J Nutr Health Aging. 2009 Mar;13(3):205-8.

Identification of novel APP/Abeta isoforms in human cerebrospinal fluid.
Portelius E, Brinkmalm G, Tran AJ, Zetterberg H, Westman-Brinkmalm A, Blennow K. Neurodegener Dis. 2009;6(3):87-94. Epub 2009 Feb 20.

Biomarkers in relation to cognitive reserve in patients with mild cognitive impairment--proof of concept.
Rolstad S, Nordlund A, Eckerström C, Gustavsson MH, Zetterberg H, Wallin A. Dement Geriatr Cogn Disord. 2009;27(2):194-200. Epub 2009 Feb 19.
78.

Reduced levels of amyloid-beta-binding proteins in cerebrospinal fluid from Alzheimer's disease patients.
Hansson SF, Andréasson U, Wall M, Skoog I, Andreasen N, Wallin A, Zetterberg H, Blennow K. J Alzheimers Dis. 2009 Feb;16(2):389-97.

Magnetic resonance imaging improves cerebrospinal fluid biomarkers in the early detection of Alzheimer's disease.
Brys M, Glodzik L, Mosconi L, Switalski R, De Santi S, Pirraglia E, Rich K, Kim BC, Mehta P, Zinkowski R, Pratico D, Wallin A, Zetterberg H, Tsui WH, Rusinek H, Blennow K, de Leon MJ. J Alzheimers Dis. 2009 Feb;16(2):351-62.

Monitoring of brain interstitial total tau and beta amyloid proteins by microdialysis in patients with traumatic brain injury.
Marklund N, Blennow K, Zetterberg H, Ronne-Engström E, Enblad P, Hillered L. J Neurosurg. 2009 Jun;110(6):1227-37.

Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis.
Mattsson N, Axelsson M, Haghighi S, Malmeström C, Wu G, Anckarsäter R, Sankaranarayanan S, Andreasson U, Fredrikson S, Gundersen A, Johnsen L, Fladby T, Tarkowski A, Trysberg E, Wallin A, Anckarsäter H, Lycke J, Andersen O, Simon AJ, Blennow K, Zetterberg H. Mult Scler. 2009 Apr;15(4):448-54. Epub 2009 Jan 19.

Transient inflammation in neurogenic regions after irradiation of the developing brain.
Kalm M, Fukuda A, Fukuda H, Ohrfelt A, Lannering B, Björk-Eriksson T, Blennow K, Márky I, Blomgren K. Radiat Res. 2009 Jan;171(1):66-76.

Can CSF biomarkers or pre-treatment progression rate predict response to cholinesterase inhibitor treatment in Alzheimer's disease?
Wallin AK, Hansson O, Blennow K, Londos E, Minthon L. Int J Geriatr Psychiatry. 2009 Jun;24(6):638-47.

Total gastrectomy causes a sustained, long-term elevation of somatostatin in plasma, independent of the mode of reconstruction in pigs.
Smedh U, Hansson L, Ekman R, Zilling T.In Vivo. 2009 Jan-Feb;23(1):99-103.

Jejunal pouch reconstruction but not preservation of duodenal passage after total gastrectomy reduces plasma cholecystokinin and pancreatic polypeptide long term in pigs.
Smedh U, Hansson L, Ekman R, Zilling T. In Vivo. 2009 Jan-Feb;23(1):93-8.

Choir singing and fibrinogen. VEGF, cholecystokinin and motilin in IBS patients.
Christina Grape RN, Theorell T, Wikström BM, Ekman R.Med Hypotheses. 2009 Feb;72(2):223-5. Epub 2008 Oct 31.

Novel biochemical markers of psychosocial stress in women.
Asberg M, Nygren A, Leopardi R, Rylander G, Peterson U, Wilczek L, Källmén H, Ekstedt M, Akerstedt T, Lekander M, Ekman R.PLoS One. 2009;4(1):e3590. Epub 2009 Jan 29.

Additional evidence for antagonistic pleiotropic effects of APOE.
Zetterberg H, Alexander DM, Spandidos DA, Blennow K. Alzheimers Dement. 2009 Jan;5(1):75.

 

  

Publikationer från 2008 med länkar till abstrakt i pubmed.

 

Soluble TNF receptors are associated with Abeta metabolism and conversion to dementia in subjects with mild cognitive impairment.
Buchhave P, Zetterberg H, Blennow K, Minthon L, Janciauskiene S, Hansson O. Neurobiol Aging. 2008 Dec 12. [Epub ahead of print]

Sympathetic and sensory nerve activation during negative pressure therapy of sternotomy wounds.
Torbrand C, Wackenfors A, Lindstedt S, Ekman R, Ingemansson R, Malmsjö M. Interact Cardiovasc Thorac Surg. 2008 Dec;7(6):1067-70. Epub 2008 Sep 10.

Apolipoprotein E polymorphism and gender difference in outcome after severe traumatic brain injury.
Ost M, Nylén K, Csajbok L, Blennow K, Rosengren L, Nellgård B.Acta Anaesthesiol Scand. 2008 Nov;52(10):1364-9.

Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?
Ohrfelt A, Grognet P, Andreasen N, Wallin A, Vanmechelen E, Blennow K, Zetterberg H. Neurosci Lett. 2009 Feb 6;450(3):332-5. Epub 2008 Nov 12.

Elevated cerebrospinal fluid levels of prostaglandin E2 and 15-(S)-hydroxyeicosatetraenoic acid in multiple sclerosis.
Mattsson N, Yaong M, Rosengren L, Blennow K, Månsson JE, Andersen O, Zetterberg H, Haghighi S, Zho I, Pratico D. J Intern Med. 2009 Apr;265(4):459-64. Epub 2008 Oct 25.

Elevated plasma levels of soluble CD40 in incipient Alzheimer's disease.
Buchhave P, Janciauskiene S, Zetterberg H, Blennow K, Minthon L, Hansson O. Neurosci Lett. 2009 Jan 23;450(1):56-9. Epub 2008 Nov 5.PMID: 18996438 [PubMed - indexed for MEDLINE]

Biomarkers reflecting different facets of Alzheimer's disease.
Zetterberg H. Eur J Neurol. 2008 Nov;15(11):1143-4. No abstract available.

The outcome of tactile touch on oxytocin in intensive care patients: a randomised controlled trial.
Henricson M, Berglund AL, Määttä S, Ekman R, Segesten K. J Clin Nurs. 2008 Oct;17(19):2624-33.

The ACE Insertion Deletion polymorphism relates to dementia by metabolic phenotype, APOEepsilon4, and age of dementia onset.
Gustafson DR, Melchior L, Eriksson E, Sundh V, Blennow K, Skoog I. Neurobiol Aging. 2010 Jun;31(6):910-6. Epub 2008 Oct 5.

Association of pro-ghrelin and GHS-R1A gene polymorphisms and haplotypes with heavy alcohol use and body mass.
Landgren S, Jerlhag E, Zetterberg H, Gonzalez-Quintela A, Campos J, Olofsson U, Nilsson S, Blennow K, Engel JA. Alcohol Clin Exp Res. 2008 Dec;32(12):2054-61. Epub 2008 Sep 25.

The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients.
Lee JM, Blennow K, Andreasen N, Laterza O, Modur V, Olander J, Gao F, Ohlendorf M, Ladenson JH.Clin Chem. 2008 Oct;54(10):1617-23. Epub 2008 Aug 14.

Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease.
Zetterberg H, Andreasson U, Hansson O, Wu G, Sankaranarayanan S, Andersson ME, Buchhave P, Londos E, Umek RM, Minthon L, Simon AJ, Blennow K. Arch Neurol. 2008 Aug;65(8):1102-7.

Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, Masters CL, Targum S, Bush AI, Murdoch R, Wilson J, Ritchie CW; PBT2-201-EURO study group. Lancet Neurol. 2008 Sep;7(9):779-86. Epub 2008 Jul 30. Erratum in: Lancet Neurol. 2009 Nov;8(11):981.

Association of APOE with age at onset of sporadic amyotrophic lateral sclerosis.
Zetterberg H, Jacobsson J, Rosengren L, Blennow K, Andersen PM. J Neurol Sci. 2008 Oct 15;273(1-2):67-9. Epub 2008 Jul 25.

Cerebrospinal fluid tau and amyloid beta42 protein in patients with myotonic dystrophy type 1.
Winblad S, Månsson JE, Blennow K, Jensen C, Samuelsson L, Lindberg C. Eur J Neurol. 2008 Sep;15(9):947-52. Epub 2008 Jul 14.

The pilot European Alzheimer's Disease Neuroimaging Initiative of the European Alzheimer's Disease Consortium.
Frisoni GB, Henneman WJ, Weiner MW, Scheltens P, Vellas B, Reynish E, Hudecova J, Hampel H, Burger K, Blennow K, Waldemar G, Johannsen P, Wahlund LO, Zito G, Rossini PM, Winblad B, Barkhof F; Alzheimer's Disease Neuroimaging Initiative. Alzheimers Dement. 2008 Jul;4(4):255-64.

Biological CSF Markers of Alzheimer's Disease.
Zetterberg H, Blennow K. Handb Clin Neurol. 2008;89:261-8. No abstract available.

Hyperphosphorylation of tau protein in superficial CNS siderosis.
Kondziella D, Zetterberg H. J Neurol Sci. 2008 Oct 15;273(1-2):130-2. Epub 2008 Jul 10.

Genetic susceptibility sets for Alzheimer's disease identified from diverse candidate loci.
Corder EH, Blennow K, Prince JA. Rejuvenation Res. 2008 Jun;11(3):667-79.

Episodic memory and speed/attention deficits are associated with Alzheimer-typical CSF abnormalities in MCI.
Nordlund A, Rolstad S, Klang O, Lind K, Pedersen M, Blennow K, Edman A, Hansen S, Wallin A. J Int Neuropsychol Soc. 2008 Jul;14(4):582-90.

Cube copying test in combination with rCBF or CSF A beta 42 predicts development of Alzheimer's disease.
Buchhave P, Stomrud E, Warkentin S, Blennow K, Minthon L, Hansson O.Dement Geriatr Cogn Disord. 2008;25(6):544-52. Epub 2008 Jun 6.

Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment.
Hansson O, Zetterberg H, Vanmechelen E, Vanderstichele H, Andreasson U, Londos E, Wallin A, Minthon L, Blennow K. Neurobiol Aging. 2010 Mar;31(3):357-67. Epub 2008 May 19.

Slowing of EEG correlates with CSF biomarkers and reduced cognitive speed in elderly with normal cognition over 4 years.
Stomrud E, Hansson O, Minthon L, Blennow K, Rosén I, Londos E. Neurobiol Aging. 2010 Feb;31(2):215-23.

Evidence that the gene encoding insulin degrading enzyme influences human lifespan.
Hong MG, Reynolds C, Gatz M, Johansson B, Palmer JC, Gu HF, Blennow K, Kehoe PG, de Faire U, Pedersen NL, Prince JA. Hum Mol Genet. 2008 Aug 1;17(15):2370-8. Epub 2008 Apr 30.

Cerebrospinal fluid markers before and after shunting in patients with secondary and idiopathic normal pressure hydrocephalus.
Tullberg M, Blennow K, Månsson JE, Fredman P, Tisell M, Wikkelsö C. Cerebrospinal Fluid Res. 2008 Apr 25;5:9.

Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization.
Klyubin I, Betts V, Welzel AT, Blennow K, Zetterberg H, Wallin A, Lemere CA, Cullen WK, Peng Y, Wisniewski T, Selkoe DJ, Anwyl R, Walsh DM, Rowan MJ. J Neurosci. 2008 Apr 16;28(16):4231-7.

The peptidergic innervation of the rat parotid gland: effects of section of the auriculo-temporal nerve and/or of otic ganglionectomy.
Khosravani N, Ekman R, Ekström J. Arch Oral Biol. 2008 Mar;53(3):238-42. Epub 2007 Nov 14

Characterization of tau in cerebrospinal fluid using mass spectrometry.
Portelius E, Hansson SF, Tran AJ, Zetterberg H, Grognet P, Vanmechelen E, Höglund K, Brinkmalm G, Westman-Brinkmalm A, Nordhoff E, Blennow K, Gobom J. J Proteome Res. 2008 May;7(5):2114-20. Epub 2008 Mar 20.

Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease.
Ewers M, Zhong Z, Bürger K, Wallin A, Blennow K, Teipel SJ, Shen Y, Hampel H. Brain. 2008 May;131(Pt 5):1252-8. Epub 2008 Mar 11.

Prediction of Alzheimer's disease using a cerebrospinal fluid pattern of C-terminally truncated beta-amyloid peptides.
Höglund K, Hansson O, Buchhave P, Zetterberg H, Lewczuk P, Londos E, Blennow K, Minthon L, Wiltfang J.Neurodegener Dis. 2008;5(5):268-76. Epub 2008 Feb 29.

Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease.
Kadir A, Andreasen N, Almkvist O, Wall A, Forsberg A, Engler H, Hagman G, Lärksäter M, Winblad B, Zetterberg H, Blennow K, Långström B, Nordberg A. Ann Neurol. 2008 May;63(5):621-31.

Non-neurological surgery results in a neurochemical stress response.
Anckarsäter R, Zetterberg H, Månsson JE, Blennow K, Anckarsäter H. J Neural Transm. 2008;115(3):397-9. Epub 2008 Feb 4.

Serum levels of S100B, S100A1B and S100BB are all related to outcome after severe traumatic brain injury.
Nylén K, Ost M, Csajbok LZ, Nilsson I, Hall C, Blennow K, Nellgård B, Rosengren L. Acta Neurochir (Wien). 2008 Mar;150(3):221-7; discussion 227. Epub 2008 Jan 14.

A highly insoluble state of Abeta similar to that of Alzheimer's disease brain is found in Arctic APP transgenic mice.
Philipson O, Hammarström P, Nilsson KP, Portelius E, Olofsson T, Ingelsson M, Hyman BT, Blennow K, Lannfelt L, Kalimo H, Nilsson LN. Neurobiol Aging. 2009 Sep;30(9):1393-405. Epub 2008 Jan 14.

CSF Mg and Ca as diagnostic markers for dementia with Lewy bodies.
Boström F, Hansson O, Gerhardsson L, Lundh T, Minthon L, Stomrud E, Zetterberg H, Londos E. Neurobiol Aging. 2009 Aug;30(8):1265-71. Epub 2008 Jan 8.

Association of complement factor H Y402H gene polymorphism with Alzheimer's disease.
Zetterberg M, Landgren S, Andersson ME, Palmér MS, Gustafson DR, Skoog I, Minthon L, Thelle DS, Wallin A, Bogdanovic N, Andreasen N, Blennow K, Zetterberg H. Am J Med Genet B Neuropsychiatr Genet. 2008 Sep 5;147B(6):720-6.

 

Publikationer från 2007 med länkar till abstrakt i pubmed.

 

Association of CFH Y402H with Alzheimer's disease
Zetterberg M, Landgren S, Andersson M, Seibt Palmér M, Gustafson DR, Skoog I, Minthon L, Thelle SD, Wallin A, Bogdanovic N, Andreasen N, Blennow K, Zetterberg H.. Online American Journal of Medical Genetics 2007; 28 Dec. 

Kinesin gene variability affects tau phosphorylation in early Alzheimer's disease
Andersson ME, Sjölander A, Andreasen N, Minthon L, Hansson O, Bogdanovic N, Jern C, Jood K, Wallin A, Blennow K, Zetterberg H. The International journal of molecular medicine. 2007;20:233-239.

Variability in the kinesin light chain 1 gene may influence risk of age-relatdet cataract
Andersson ME, Zetterberg M, Tasa G, Seidt Palmér M, Juronen E, Teesalu P, Blennow K, Zetterberg H. Accepted for publication in Molecular Vision. 2007;13:993-996.

Amyloid b quantification in CSF: comparison between chromatographic and immunochemical methods
Simonsen AH, Hansson SF, Ruetschi U, McGuire J, Podust VN, Davies HA, Mehta P, Waldemar G, Zetterberg H, Andreasen N, Wallin A, Blennow K. Dement Geriatr Cogn Disord 2007;23:246-250.

 Novel Panel of Cerebrospinal Fluid Biomarkers for the Prediction of Progression to Alzheimer Dementia in Patients With Mild Cognitive Impairment
Simonsen AH, McGuire J, Hansson O, Zetterberg H, Podust VN, Davies HA, Waldemar G, Minthon L, Blennow K. Arch Neurol 2007;64:366-370. 

 Ventricular cerebrospinal fluid neurofilament protein levels decrease in parallel with white matter pathology after shunt surgery in normal pressure hydrocephalus
Blennow K, Månsson JE, Fredman P, Tisell M, Wikkelsø C. Eur J Neurol 2007;14:248-254. 

Evaluation of sample fractionation using micro-scale liquid-phase isoelectric focusing on mass spectrometric identification and quantitation of proteins in a SILAC experiment
Thorsell A, Portelius E, Westman-Brinkmalm A. Rapid Commun Mass Spectrom 2007;21:771-778.

Acetylcholine synthesis, muscarinic receptor subtypes, neuropeptides and secretion of ferret salivary glands with special reference to the zygomatic gland.
Khosravani N, Ekman R, Ekström J. Arch Oral Biol. 2007 May;52(5):417-26. Epub 2006 Nov 22

 Prediction of Alzheimer’s disease using CSF Ab42/Ab40 ratio in patients with MCI
Hansson O, Zetterberg H, Buchhave P, Andreasson U, Londos E, Minthon L and Blennow K.Dement Geriatr Cogn Disord. 2007;23(5):316-20. Epub 2007 Mar 19. 

Hypertension in spontaneously hypertensive rats occurs despite low plasma levels of homocysteine
Kondziella D, Zetterberg H, Haugen E, Fu M. Physiol Res. 2008;57(3):487-90. Epub 2007 Feb 8 

Molecular and biological markers for Alzheimer’s disease
Zetterberg H, Blennow K. Submitted to Neurobiology of Alzheimer’s Disease, Oxford University Press. Eds. D Dawbarn & SJ Allen. 2007. In press. 

Apolipoprotein E polymorphisms in patients with primary open-angle glaucoma
Zetterberg M, Tasa G, Palmér MS, Juronen E, Veromann S, Teesalu P, Blennow K, Zetterberg H.Am J Ophthalmol. 2007 Jun;143(6):1059-60. 

Methylenetetrahydrofolate reductase genetic polymorphisms in patients with primary open-angle glaucoma
Zetterberg M, Tasa G, Palmér MS, Juronen E, Veromann S, Teesalu P, Blennow K, Zetterberg H.Ophthalmic Genet. 2007 Jun;28(2):47-50.

 

 

Publikationer från 2006 med länkar till abstrakt i pubmed.

 

An Alzheimer’s disease-specific b-amyloid fragment signature in cerebrospinal fluid
Portelius E, Zetterberg H, Andreasson U, Brinkmalm G, Andreasen N, Wallin A, et al. Neurosci Lett. 2006 Dec 6;409(3):215-9. Epub 2006 Oct 17. 

 Vagus nerve stimulation in patients with Alzheimer’s disease: Additional follow-up results of a pilot study through 1-year
Merrill CA, Jonsson MAG, Minthon L, Ejnell H, C-son Silander H, Blennow K, Karlsson M, Nordlund A, Rolstad S, Warkentin S, Ben-Menachem E, Sjögren MJC.J Clin Psychiatry 2006;67:1171-1178.

 Neurochemical aftermath of amateur boxing
Zetterberg H, Hietala MA, Jonsson M, Andreasen N, Styrud E, Karlsson I, Edman Å, Popa C, Rasulzada A, Wahlund LO, Mehta PD, Rosengren L, Blennow K, Wallin A. Arch Neurol 2006;63:1277-1280.

 Cystatin C in Cerebrospinal Fluid and Multiple Sclerosis
Hansson SF, Hviid-Simonsen A, Zetterberg H, Andersen O, Haghighi S, Fagerberg I, Andreasson U, Westman-Brinkmalm A, Wallin A, Rüetschi U, Blennow K. Ann Neurol 2006:3651-8

CSF–Neurofilament correlates with outcome after aneurysmal subarachnoid haemorrhage
Nylén K, Csajbok LZ Öst M, Rashid A, Karlsson J-E, Blennow K, Nellgård B, Rosengren L. Neurosci Lett 2006;404:132-136.

 The TAQI DRD2 A1 allele is associated with alcohol-dependence although its effect is small
Berggren U, Fahlke C, Aronsson E, Karanti A, Eriksson M, Blennow K, Thelle D, Zetterberg H, Balldin J. Alcohol and Alcoholism 2006;41:479-485. 

The cathepsin D rs17571 polymorphism: effects on CSF concentrations in Alzheimer disease 
Riemenschneider M, Blennow K, Wagenpfeil S, Andreasen N, Prince JA, Laws SM, Förstl H, Kurz A. . Hum Mutat 2006;27:532-537. 

Determination of b-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry
Portelius E, Westman-Brinkmalm A, Zetterberg H, Blennow K. J Proteome Res 2006;5:1010-1016. 

Clusterin in cerebrospinal fluid: Analysis of carbohydrates and quantification of native and glycosylated forms
Nilselid AM, Davidsson P, Nägga K, Andreasen N, Fredman P, Blennow K. . Neurochem Int 2006;48:718-728.

Low Serum Potassium in Mid Life Associated with Decreased Cerebrospinal Fluid b42 in Late Life
Mielke MM, Zandi PP, Blennow K, Gustafson D, Sjögren M, Rosengren L, Skoog I. Alzheimer Dis Assoc Disord 2006;20:30-36. 

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study
Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Lancet Neurol 2006;5:228-34. 

Increased serum-GFAP in patients with severe traumatic brain injury is related to outcome
Nylén K, Öst M, Csajbok L, Nilsson I, Nellgård B, Blennow K, Rosengren L. J Neurol Sci 2006;240:85-91.

Towards compendia of negative genetic association studies: an example for Alzheimer disease
Blomqvist ME, Reynolds C, Katzov H, Feuk L, Andreasen N, Bogdanovic N, Blennow K, Brookes AJ, Prince JA. Hum Genet 2006;119:29-37.

 Quantitative trait loci in ABCA1 modify cerebrospinal fluid amyloid-b1-42 and plasma apolipoprotein levels
Katzov H, Bennet AM, Höglund K, Wiman B, Lutjohann D, Brookes AJ, Andreasen N, Blennow K, De Faire U, Prince JA. J Hum 

CSF biomarkers for Alzheimer’s disease: levels of b-amyloid, tau and phosphorylated tau relate to clinical symptoms and survival
Wallin ÅK, Blennow K, Andreasen N, Minthon L. Dement Geriatr Cogn disord 2006;21:131-138.

 Methylenetetrahydrofolate reductase genetic polymorphism in patients with cataract
Zetterberg M, Tasa G, Prince JA, Palmér M, Juronen E, Veromann S, Teesalu P, Karlsson JO, Blennow K, Zetterberg H. Am J Ophthalmol 2005;140:932-934.

Diagnostic value of 14-3-3beta immunoblot and T-tau/P-tau ratio in clinically suspected Creutzfeldt-Jakob disease
Blennow K, Johansson A, Zetterberg H. Int J Mol Med 2005;16:1147-1149.

Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt-Jakob disease
Buerger K, Otto M, Teipel S, Zinkowski R, Blennow K, DeBernardis J, Kerkman, D, Schröder J, Schönknecht P, Cepek L, McCulloch C, Möller HJ, Wiltfang J, Kretzschmar H, Hampel H. Neurobiol Aging 2006;27:10-15. 

Zetterberg H, Rymo L.EBNA2 Transcription Regulation in EBV Latency. In Epstein-Barr virus: Pathogenesis, Molecular Biology and Infectious Control Ed. ES Robertson. Horizon Press. 2006.

Zebrafish lacking Alzheimer presenilin enhancer 2 (Pen-2) demonstrate excessive p53-dependent apoptosis and neuronal loss Campbell WA, Yang H, Zetterberg H, Baulac S, Sears JA, Liu T, Wong ST, Zhong TP, Xia W. J Neurochem. 2006;96:1423-40. 

Zetterberg H, Blennow K, Xia W.RNA interference: applications in research on amyloidogenesis in Alzheimer's disease. Trends in RNA Res. Ed. PA McNamara. Nova Science Publishers. 2006. ISBN: 1-59454-506-5. 

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Lancet Neurol. 2006;5:228-34. 

The Role of Biomarkers in Clinical Trials for Alzheimer Disease Thal LJ, Kantarci K, Reiman EM, Klunk WE, Weiner MW, Zetterberg H, Galasko D, Pratico D, Griffin S, Schenk D, Siemers E. Alzheimer Dis Assoc Disord. 2006;20:6-15.

 The cytosolic loop of the gamma-secretase component presenilin enhancer 2 (Pen-2) protects zebrafish embryos from apoptosis Zetterberg H, Campbell WA, Yang HW, Xia W. J Biol Chem. 2006;281:11933-9.

Determination of b-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation mass spectrometry Portelius E, Westman-Brinkmalm A, Zetterberg H, Blennow K. J Proteome Res. 2006;5:1010-6. 

Alzheimer’s disease
Blennow K, De Leon MJ, Zetterberg H. Lancet. 2006;368:387-403. 

Regarding the inconsistency of “optimal” cutpoints obtained using two criteria based on the receiver operating characteristic curve
Zetterberg H. Am J Epidem. 2006;164:707-8. 

Neurochemical aftermath of amateur boxing
Zetterberg H, Hietala MA, Jonsson M, Andreasen N, Styrud E, Karlsson I, Edman Å, Popa C, Rasulzada A, Wahlund LO, Mehta PD, Rosengren L, Blennow K, Wallin A. Arch Neurol. 2006;63:1277-80. 

Differences in psychiatric and somatic diagnoses between the TaqI A1/A2 DRD2 genotypes in alcohol-dependent subjects
Berggren U, Fahlke C, Eriksson M, Blennow K, Thelle D, Zetterberg H, Balldin J. Alcohol Alcohol. 2006, Epub ahead of print. 

Cerebrospinal fluid protein reactions during non-neurological surgery
Anckarsäter R, Vasic N, Jidéus L, Kristiansson M, Zetterberg H, Blennow K, Anckarsäter H. Acta Neurol Scand. 2006, in press.

Cerebrospinal fluid beta-amyloid 1-42 concentration may predict cognitive decline in older women
Gustafson DR, Skoog I, Rosengren L, Zetterberg H, Blennow K. J Neurol Neurosurg Psychiatry. 2007 May;78(5):461-4. Epub 2006 Nov 10. 

An Alzheimer’s disease-specific b-amyloid fragment signature in cerebrospinal fluid
Portelius E, Zetterberg H, Andreasson H, Brinkmalm G, Andreasen N, Wallin A, Westman-Brinkmalm A, Blennow K. Neurosci Lett. 2006;409:215-9. 

Elevated cerebrospinal fluid F2-isoprostane levels indicating oxidative stress in healthy siblings of multiple sclerosis patients
Mattsson N, Haghighi S, Andersen O, Yao Y, Rosengren L, Blennow K, Pratico D, Zetterberg H. Neurosci Lett. 2006 Dec 30; [Epub ahead of print].

 

 

Sidansvarig: Staffan Persson|Sidan uppdaterades: 2014-09-18
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?